- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03595553
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 1)
A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)
Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of demonstrating an improved Sustained Clinical Response rate in subjects treated with ridinilazole as compared to subjects treated with vancomycin.
A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these attributes with a comparable safety profile. A high fecal concentration of ridinilazole and little systemic exposure were noted.
The rationale for this phase 3 study is to confirm the improvement in sustained clinical response of CDI over vancomycin and to compare the safety and tolerability of ridinilazole to that of vancomycin.
Ridinilazole plasma concentration will be assessed in a subset of patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, BI900AVG
- Instituto Medico Platense
-
Buenos Aires, Argentina, C1199ABB
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentina, C1221ADC
- Hospital Ramos Mejía
-
Cordoba, Argentina, X5016KEH
- Hospital Privado Centro Medico Cordoba
-
Salta, Argentina, CP4400
- Instituto Médico Alas
-
-
Buenos Aires
-
El Talar, Buenos Aires, Argentina, 1608
- Centro Médico Talar
-
-
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital
-
-
Queensland
-
Birtinya, Queensland, Australia, 4575
- Sunshine Coast University Hospital
-
South Brisbane, Queensland, Australia, 4101
- Mater Misericordiae
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Medical Center
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Fiona Stanley Hospital
-
-
-
-
-
Sao Paulo, Brazil, 01327-001
- Hospital Alemao Oswaldo Cruz
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30150221
- Santa Casa de Misericordia de Belo Horizonte
-
Belo Horizonte, Minas Gerais, Brazil, 30110-936
- Unidade de Pesquisa - NCS - Hospital Felício Rocho
-
Belo Horizonte, Minas Gerais, Brazil, 30140-030
- Hospital Vera Cruz
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90020090
- Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
- Hospital das Clinicas de Porto Alegre
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90160-092
- Hospital Ernesto Dornelles
-
-
Sao Paulo
-
Sao Jose do Rio Preto, Sao Paulo, Brazil, 15090-000
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
-
-
-
-
-
Blagoevgrad, Bulgaria, 2700
- "MHAT - Blagoevgrad, EOOD Department of Gastroenterology"
-
Sliven, Bulgaria, 8800
- DCC1-Sliven Ltd.
-
Sofia, Bulgaria, 1431
- DCC Alexandrovska
-
Sofia, Bulgaria, 1612
- Medical center - Izgrev
-
-
Kyustendil
-
Dupnitsa, Kyustendil, Bulgaria, 2600
- MHAT "Sv.Ivan Rilski-2003"OOD
-
-
-
-
-
Quebec, Canada, G1V 4G5
- Institut Universitaire de Cardiologie et de Pneumologie de Québec- ULaval
-
Quebec, Canada, J7Z 5T3
- Recherche Médicale St-Jérôme Inc
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Foothills Medical Centre, South Tower
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1C 6Z8
- Moncton Hospital/Horizon Health Network
-
-
Ontario
-
Oshawa, Ontario, Canada, L1G 2B9
- Lakeridge Health
-
-
Quebec
-
Montréal, Quebec, Canada, H2X 1R9
- Centre Hospitalier de l'Université de Montréal
-
Trois-Rivières, Quebec, Canada, G8Z 3R9
- Centre Intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec
-
-
-
-
-
Athens, Greece, 10676
- General Hospital of Athens ''Evangelismos'
-
Athens, Greece, 115-28
- General Hospital of Athens ''Alexandra''
-
Athens, Greece, 11527
- "Pathophysiology Department Athens University Medical School"
-
Athens, Greece, 12462
- " ATTIKON University Hospital"
-
Athens, Greece, 15121 Marousi
- "'Hygeia'' Hospital 2nd Department of Medicine and Infectious Diseases"
-
Heraklion, Greece, 71110
- University Hospital of Heraklion
-
Patras, Greece, 265 04
- University Hospital of Patras
-
Piraeus, Greece, 185 -36
- ''Tzaneio'' General Hospital of Piraeus
-
-
-
-
-
Balassagyarmat, Hungary, 2660
- Dr. Kenessey Albert Kórház Rendelőintézet, Tüdőgyógyászati Aktív Osztály
-
Budapest, Hungary, H-1097
- "Dél-Pesti Centrumkórház-OHII Szent László Kórház Infektológiai Osztály "
-
Budapest, Hungary, H-1122
- Országos Korányi Pulmonológiai Intézet, Központi Intenzív osztály
-
Békéscsaba, Hungary, 5600
- Békés Megyei Központi Kórház Dr. Réthy Pál Tagkórház IV. Belgyógyászat - 2. Gasztroenterológia
-
Miskolc, Hungary, 3529
- CRU Hungary Kft BAZ Megyei Kórház és Egyetemi Oktatókórház, Szent Ferenc Tagkórház
-
Pécs, Hungary, H-7623
- "Pécsi Tudományegyetem I. sz. Belgyógyászat i Klinika, Infektológiai tanszék"
-
Pécs, Hungary, H-7624
- Pécsi Tudományegyetem Klinikai Központi Gyógyszertár
-
Szentes, Hungary, H-6600
- Csongrad County Dr. Bugyi Istvan Hospital, Dept. Of Internal Medicine
-
Vác, Hungary, 2600
- Javorszy Odon Hospital
-
-
Békés
-
Gyula, Békés, Hungary, 5700
- Békés Megyei Központi Kórház Pándy Kálmán Tagkórház, Infektológia-Hepatológia Osztály
-
-
Pest Megye
-
Kistarcsa, Pest Megye, Hungary, 2143
- Pest Megyei Flór Ferenc Kórház, V. Belgyógyászat
-
-
-
-
-
Junggu, Korea, Republic of, 04551
- Inje University Seoul Paik Hospital
-
Seoul, Korea, Republic of, 03181
- Kangbuk Samsung Hospital
-
Seoul, Korea, Republic of, 05355
- Kangdong Sacred Heart Hospital
-
Soeul, Korea, Republic of, 08307
- Korea University Guro Hospital
-
Soeul, Korea, Republic of, 5505
- Asan Medical Center
-
-
Gangwon-do
-
Chuncheon, Gangwon-do, Korea, Republic of, 24253
- Hallym University Chuncheon Sacred Heart Hospital
-
-
Gangwondo
-
Ilsan-dong, Gangwondo, Korea, Republic of, 26426
- WonJu Severance Christian Hospital
-
-
Gyeonggi-do
-
Ansan-si, Gyeonggi-do, Korea, Republic of, 15355
- Korea University Ansan Hospital
-
Guri-Si, Gyeonggi-do, Korea, Republic of, 11923
- Hanyang University Guri Hospital
-
-
Seoul
-
Ansan, Seoul, Korea, Republic of, 04763
- Hanyang University Seoul Hospital
-
Anyang-si, Seoul, Korea, Republic of, 07441
- Hallym University Kangnam Sacred Heart Hospital
-
Daegu, Seoul, Korea, Republic of, 41944
- Kyungpook National University Hospital
-
Daegu, Seoul, Korea, Republic of, 42415
- Yeungnam University Medical Center
-
Irwon-dong, Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
-
Yeongnam
-
Daegu, Yeongnam, Korea, Republic of, 42601
- Keimyung University Dongsan Hospital
-
-
-
-
Auckland
-
Takapuna, Auckland, New Zealand, 0740
- Waitemata District Health Board WDHB North Shore Hospital
-
-
Taranki
-
New Plymouth, Taranki, New Zealand, 4310
- Taranaki District Health Board TDHB - Taranaki Base Hospital
-
-
Waikato
-
Hamilton, Waikato, New Zealand, 3240
- Waikato District Health Board Waikato Hospital
-
-
-
-
-
Bochnia, Poland, 32-700
- SP ZOZ w Bochni Szpital Powiatowy im. B. Marty Wieckiej
-
Bochnia, Poland, 32-700
- Szpital Bocheński SP ZOZ w Bochni
-
Bydgoszcz, Poland, 85-030
- Klinika Chorób Zakaźnych i Hepatologii Wojewódzki Szpital Obserwacyjno-Zakaźny im. Tadeusza Browicza
-
Chorzów, Poland, 41-500
- Szpital Specjalistyczny w Chorzowie
-
Katowice, Poland, 40-211
- Szpital Zakonu Bonifratrow
-
Krakow, Poland, 30-539
- Specjalistyczne Gabinety Sp z o.o.
-
Rzeszow, Poland, 35-302
- Korczowski Bartosz Gabinet
-
Sopot, Poland, 81-756
- Endoskopia Sp. z o.o.
-
Warszawa, Poland, 02-507
- Centralny Szpital Kliniczny MSWiA Klinika Chorób Wewnętrznych i Gastroenterologii
-
Warszawa, Poland, 02-507
- Klinika Chorób Wewnętrznych i Gastroenterologii z Pododdziałem Leczenia Nieswoistych Chorób Zapalnych Jelit Centralny Szpital Kliniczny MSWiA
-
Wroclaw, Poland, 51-149
- Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego we Wrocławiu; I Oddział Chorób Zakaźnych
-
-
Podkarpackie
-
Rzeszów, Podkarpackie, Poland, 35-302
- Gabinet Lekarski Bartosz Korczowski
-
-
-
-
-
Bucuresti, Romania, 010825
- SUUMC-Boli infectioase
-
Bucuresti, Romania, 030303
- Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes"
-
Bucuresti, Romania, 11025
- S.C. Sana Monitoring Srl
-
Bucuresti, Romania, 30303
- Spitalul Clinic de Boli Infectioase si Tropicale
-
Caracal, Romania, 235200
- Spitalul Minicipal Caracal
-
Constanta, Romania, 900709
- Spitalul Clinic de Boli Infectioase Constanta
-
Iasi, Romania, 700722
- Spitalul Clinic de Boli Infectioase- Sfanta Parascheva
-
Iaşi, Romania, 700722
- Spitalul Clinic de Boli Infectioase
-
Timișoara, Romania, 300723
- Spitalul Clinic Judetean de Urgenta Timisoara
-
-
-
-
-
Moscow, Russian Federation, 115516
- " State Budgetary Institution of Healthcare "City Clinical Hospital of n.a. V.M.Buyanova" "
-
Novosibirsk, Russian Federation, 630051
- State budget healthcare institution of Novosibirsk region "City clinical hospital #2"
-
-
-
-
-
Barakaldo, Spain, 48903
- Hospital Universitario Cruces
-
Barcelona, Spain, 8041
- Hospital de La Santa Creu i Sant Pau
-
Córdoba, Spain, 14004
- Hospital Universitario Reina Sofía. Hospital Provincial
-
Donostia, Spain, 20014
- "Hospital Universtiario Donostia "
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Marañon
-
Santander, Spain, 39008
- "Hospital Universitario Marqués de Valdecilla "
-
Sevilla, Spain, 41014
- Hospital Universitario de Balme
-
Tarragona, Spain, 43204
- Hospital Universitari Sant Joan de Reus
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama - Birmingham
-
-
Arizona
-
Sun City, Arizona, United States, 85351
- GI Alliance - Arizona Digestive Health - Sun City
-
-
California
-
Los Angeles, California, United States, 90095
- David Geffen School of Medicine at UCLA
-
Mission Hills, California, United States, 91345
- Facey Medical Foundation
-
Redding, California, United States, 96601
- Paradigm Clinical Research Centers, Inc
-
Sacramento, California, United States, 95817
- University of California Davis
-
-
Florida
-
Fort Pierce, Florida, United States, 34982
- Midway Immunology and Research Center
-
Lighthouse Point, Florida, United States, 33064
- Alliance Medical Research LLC
-
Miami, Florida, United States, 33165
- Phoenix Medical Research LLC
-
Miami Lakes, Florida, United States, 33014
- San Marcus Research
-
Naples, Florida, United States, 31402
- Gasteroenterology Group of Naples
-
Orlando, Florida, United States, 32819
- HeuerMD Research Inc
-
Pembroke Pines, Florida, United States, 33026
- Pines Care Research Center Inc.
-
Saint Petersburg, Florida, United States, 33713
- Professional Health Care of Pinellas
-
Seminole, Florida, United States, 33777
- Bardmoor GastroEnterology
-
Zephyrhills, Florida, United States, 33542
- Florida Medical Clinic P.A.
-
-
Georgia
-
Decatur, Georgia, United States, 30333
- Infectious Disease Specialists of Atlanta
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404
- Grand Teton Research Group PLLC
-
-
Illinois
-
Glenview, Illinois, United States, 60026
- GI Alliance - Illinois Gastro Group - Glenview
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
Peoria, Illinois, United States, 61603
- UnityPoint Health Peoria/Proctor
-
Springfield, Illinois, United States, 62702
- Southern Illinois University School of Medicine
-
Urbana, Illinois, United States, 61801
- Carle Foundation Hospital
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- The University of Kansas Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland School of Medicine
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01608-1216
- St. Vincent Hospital
-
-
Michigan
-
Detroit, Michigan, United States, 48201-2020
- Harper Hospital Department of Pharmacy Services
-
Detroit, Michigan, United States, 48201
- Detroit Receiving Hospital Department of Pharmacy Services
-
Flint, Michigan, United States, 48504-4730
- Aa Mrc Llc
-
Royal Oak, Michigan, United States, 48073-6712
- William Beaumont Hospital
-
Southfield, Michigan, United States, 48034
- Revival Research Institute, LLC.
-
-
Montana
-
Butte, Montana, United States, 59701
- Mercury Street Medical Group PLLC
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
- AB Clinical Trials
-
-
New York
-
Bronx, New York, United States, 10468
- James J. Peters VAMC
-
New York, New York, United States, 10021
- New York Presbyterian Hospital Weill Cornell
-
-
North Carolina
-
Greenville, North Carolina, United States, 27834
- ECU Adult Specialty Care
-
Winston-Salem, North Carolina, United States, 27103
- PMG Research of Winston-Salem
-
-
Ohio
-
Toledo, Ohio, United States, 43608
- St. Vincent Mercy Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Monument Health Clinical Research
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404-3230
- Chattanooga Research and Medicine CHARM
-
-
Texas
-
Arlington, Texas, United States, 76012
- GI Alliance - Texas Digestive Disease Consultants - Arlington
-
Cedar Park, Texas, United States, 78613
- GI Alliance - Texas Digestive Disease Consultants - Cedar Park
-
Conroe, Texas, United States, 77304
- DM Clinical Research (Conroe Regional Hospital)
-
Lampasas, Texas, United States, 76550
- FMC Science
-
San Marcos, Texas, United States, 78666
- GI Alliance - Texas Digestive Disease Consultants - San Marcos
-
Webster, Texas, United States, 77598
- GI Alliance - Texas Digestive Disease Consultants - Webster
-
-
Virginia
-
Lynchburg, Virginia, United States, 24501
- Infectious Diseases Associates of Central VA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients are eligible to be included in the study only if all the following criteria apply:
- Patient must be at least 18 years of age, at the time of signing the informed consent.
- Have signs and symptoms of CDI including diarrhea such that in the Investigator's opinion, CDI antimicrobial therapy is required. Diarrhea is defined as a change in bowel habits, with ≥3 unformed bowel movements (UBMs) (5, 6 or 7 on the Bristol Stool Chart) in the 24 h prior to randomization.
- Have the presence of either toxin A and/or B of C. difficile in the stool determined by a positive free toxin test (using a Sponsor agreed test). The stool sample must be current (produced within 72 hours prior to randomization).
Male or Female
Male patients:
• A male patient must agree to use contraception as detailed in Section 10.4 of this protocol during the treatment period and for at least 30 days after the last dose of study treatment and refrain from donating sperm during this period.
Female patients:
• A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: i. Not a woman of childbearing potential (WOCBP) OR ii. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 30 days after the last dose of study treatment.
- Has provided documented signed informed consent and any authorizations required by local law (e.g. Protected Health Information [PHI]). If unable to read, understand and sign the informed consent form a legally authorized representative (LAR) may provide consent on the patient's behalf if permitted by the Institutional Review Board (IRB)/Ethics Committee (EC).
Exclusion Criteria
Patients are excluded from the study if any of the following criteria apply:
- Have had more than one prior episode of CDI in the previous 3 months or more than 3 episodes in the past 12 months prior to randomization.
- Have a history of chronic diarrheal disease including inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- Have had a positive diagnostic test for other GI pathogens, considered to be clinically relevant, within 2 weeks of randomization.
- Have had major gastrointestinal (GI) surgery (e.g. significant bowel resection) within 3 months of randomization (this does not include appendectomy). The presence of a colostomy or ileostomy or likely requirement of an ostomy during the study.
- Have life threatening or fulminant CDI with evidence of hypotension, septic shock, peritoneal signs or absence of bowel sounds, or toxic megacolon.
- History of bone marrow or hematopoietic stem cell transplant at any time or a known current history of a severely compromised/suppressed immune system that, in the opinion of the Investigator, would make the patient unsuitable for the study.
- Have had more than the equivalent of 24 hours of dosing of antimicrobial treatment active against the current episode of CDI prior to randomization. (i.e. more than four doses of oral vancomycin, two doses of fidaxomicin or three doses of metronidazole).
- Prior or current use of anti-toxin antibodies including bezlotoxumab within the past 6 months prior to randomization.
- Are unable to discontinue products used affecting disease progression at randomization.
- Has been involved in a clinical trial and received an investigational medicinal product for indications other than CDI within 1 month or five half-lives (whichever is longer) or within 3 months if the investigational medical product was for CDI.
- Have received an investigational vaccine against C. difficile.
Patients that the Investigator feels are inappropriate for the study this would include those;
- with any other condition that, in the Investigator's judgment, would make the patient unsuitable for inclusion in the study.
- who, in the opinion of the Investigator, are not likely to complete the study for whatever reason, e.g. short life expectancy.
- with known hypersensitivity or intolerance to ridinilazole, vancomycin, and/or their excipients
- who are unwilling or unable to comply with protocol requirements, e.g. complete the full course of study treatment per schedule, attend study visits, report diarrhea/suspected recurrence, provide stool samples, ingest capsules/tablets or blood draws.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ridinilazole
ridinilazole 200mg bid
|
ridinilazole (200 mg bid)
Other Names:
|
Active Comparator: vancomycin
vancomycin 125 mg qid
|
vancomycin (125 mg qid)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Sustained Clinical Response (SCR) Defined as Clinical Response and no Recurrence of CDI Through 30 Days Post End of Treatment (EOT).
Time Frame: Day 40
|
This primary outcome measures the number of participants with Sustained Clinical Response (SCR).
SCR is defined as Clinical Response and no recurrence of CDI through 30 days post End of Treatment (EOT).
At D40, D70 and D100 the Investigator or medically qualified designee will determine if the patient has a sustained clinical response or experienced RECURRENCE since the previous assessment.
The Investigator will assess cure/failure and recurrence based on available information which includes, but is not limited to, improvement from baseline in the number of UBMs, signs & symptoms of CDI, and the requirement for CDI medication.
The Investigator should assess cure/failure in a way that best reflects the Investigator's standard clinical practice.
|
Day 40
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Cure
Time Frame: Day 12
|
defined as the resolution of diarrhea (<3 UBMs in the 1-day period immediately prior to EOT, that is maintained for 2 days after EOT).
|
Day 12
|
Clinical Response
Time Frame: Day 12
|
defined as
|
Day 12
|
Sustained Clinical Response Over 60 Days
Time Frame: Day 70
|
defined as Clinical Response and no recurrence of CDI through 60 days post EOT
|
Day 70
|
Sustained Clinical Response Over 90 Days
Time Frame: Day 100
|
defined as Clinical Response and no recurrence of CDI through 90 days post EOT
|
Day 100
|
Relative Abundance of the 3 Main Bile Acid Groups (Conjugated Primary, Primary and Secondary Bile Acids) From Baseline to EOT.
Time Frame: Day 10
|
This secondary outcome measures the relative abundance of the 3 main Bile Acid Groups (Conjugated Primary, Primary and Secondary Bile Acids) from Baseline to EOT.
|
Day 10
|
Percentage of Change of α-diversity (Shannon Index) of the Microbiota in Stool Samples From Baseline to EOT.
Time Frame: Day 10
|
This secondary outcome measures the percentage of change of α-diversity (Shannon Index) of the microbiota in stool samples from baseline to EOT.
Shannon index is a weighted statistic measuring both species richness and evenness.
The Shannon Index is calculated by taking the relative abundance of each species and sums the relative abundance times the natural log of the relative abundance for each species.
The value is converted into a positive value by times minus one.
A higher Shannon Index means higher diversity
|
Day 10
|
Measure of β-diversity of the Gut Microbiota Between Baseline and EOT Stool Samples (Bray-Curtis Index/Dissimilarity).
Time Frame: Day 10
|
This secondary outcome measures the β-diversity of the gut microbiota in stool samples from baseline to EOT.
Bray-Curtis index/dissimilarity measures how different two samples are in the microbiome composition.
The Bray-Curtis dissimilarity is graded between 0 and 1, where 0 means the two samples have the same composition (that is they share all the species and every species has the same abundance), and 1 means the two samples do not share any species.
|
Day 10
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Lori Styles, MD, Summit Therapeutics
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMT19969/C004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridioides Difficile Infection
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingClostridioides Difficile Infection RecurrenceItaly
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
Hellenic Institute for the Study of SepsisCompletedMortality | Clostridioides Difficile Infection | Organ Dysfunction Syndrome | Stool Microbiome | Clostridioides Difficile Infection RecurrenceGreece
-
Christian HvasInnovation Fund DenmarkActive, not recruitingClostridium Difficile Infection | Clostridioides Difficile InfectionDenmark
-
Hanyang University Seoul HospitalPfizer; Korean Center for Disease Control and PreventionUnknownClostridium Difficile Infection
-
Acurx Pharmaceuticals Inc.Active, not recruitingClostridium Difficile InfectionUnited States
-
Summit TherapeuticsCompletedClostridioides Difficile InfectionUnited States, Spain, France, Canada, Belgium, Israel, Chile, Belarus, Latvia, Germany, Romania, Lithuania, Mexico, Czechia, Estonia, Georgia, Peru
-
Novozymes A/SEstimates OYNot yet recruitingClostridium Difficile Infection RecurrenceUnited States
-
Adiso TherapeuticsCompletedClostridium Difficile Infection RecurrenceUnited States, Canada
Clinical Trials on Ridinilazole
-
Summit TherapeuticsCompletedClostridium Difficile InfectionUnited Kingdom, United States, Czechia
-
Summit TherapeuticsCompletedClostridioides Difficile InfectionUnited States, Spain, France, Canada, Belgium, Israel, Chile, Belarus, Latvia, Germany, Romania, Lithuania, Mexico, Czechia, Estonia, Georgia, Peru
-
Summit TherapeuticsDepartment of Health and Human ServicesTerminatedClostridioides Difficile InfectionUnited States